ReviewCancers2018
Fusogenic Viruses in Oncolytic Immunotherapy.
Review in Cancers, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 47 citations in OpenAlex.
- Oncolytic virotherapy with chimeric rVSV-NDV causes tumor-specific immunity in a DC-activation-dependent manner.Molecular therapy. Oncology · 2026Article
- Article
- Syncytial death mediated by oncolytic rVSV-NDV dynamically activates immunogenic apoptosis and necroptosis in human lung cancer cells.Molecular therapy. Oncology · 2025Article
- Antibiotic-mediated selection of randomly mutagenized and cytokine-expressing oncolytic viruses.Nature biomedical engineering · 2025Article
- Cell-derived Newcastle disease virus variant with two amino acid substitutions near cleavage site of F shows favorable traits as oncolytic virus.Molecular therapy. Oncology · 2025Article
- Development and Characterization of an Oncolytic Human Adenovirus-Based Vector Co-Expressing the Adenovirus Death Protein and p14 Fusion-Associated Small Transmembrane Fusogenic Protein.International journal of molecular sciences · 2024Article
- A Novel Chimeric Oncolytic Virus Mediates a Multifaceted Cellular Immune Response in a Syngeneic B16 Melanoma Model.Cancers · 2024Article
- Oncolytic varicella-zoster virus engineered with ORF8 deletion and armed with drug-controllable interleukin-12.Journal for immunotherapy of cancer · 2024Article
- Histone deacetylase inhibitor boosts anticancer potential of fusogenic oncolytic vaccinia virus by enhancing cell-cell fusion.Cancer science · 2024Article
- Cell Fusion and Syncytia Formation in Cancer.Results and problems in cell differentiation · 2024Review
- Mechanisms of Cell Fusion in Cancer.Results and problems in cell differentiation · 2024Review
- Breaking the barriers in cancer care: The next generation of herpes simplex virus-based oncolytic immunotherapies for cancer treatment.Molecular therapy oncolytics · 2023Review
- Clinical Advances and Future Directions of Oncolytic Virotherapy for Head and Neck Cancer.Cancers · 2023Review
- Synthetic virology approaches to improve the safety and efficacy of oncolytic virus therapies.Nature communications · 2023Article
- Extracellular Events Involved in Cancer Cell-Cell Fusion.International journal of molecular sciences · 2022Review
- Tumor Temperature: Friend or Foe of Virus-Based Cancer Immunotherapy.Biomedicines · 2022Review
- A Three-Dimensional Organoid Model of Primary Breast Cancer to Investigate the Effects of Oncolytic Virotherapy.Frontiers in molecular biosciences · 2022Article
- Cell-Cell Fusion Mediated by Viruses and HERV-Derived Fusogens in Cancer Initiation and Progression.Cancers · 2021Review
- Potent anti-tumor effects of receptor-retargeted syncytial oncolytic herpes simplex virus.Molecular therapy oncolytics · 2021Article
- Use of cell fusion proteins to enhance adenoviral vector efficacy as an anti-cancer therapeutic.Cancer gene therapy · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oncolytic viruses are under intense development and have earned their place among the novel class of cancer immunotherapeutics that are changing the face of cancer therapy. Their ability to specifically infect and efficiently kill tumor cells, while breaking immune tolerance and mediating immune responses directed against the tumor, make oncolytic viruses highly attractive candidates for immunotherapy. Increasing evidence indicates that a subclass of oncolytic viruses, which encodes for fusion proteins, could outperform non-fusogenic viruses, both in their direct oncolytic potential, as well as their immune-stimulatory properties. Tumor cell infection with these viruses leads to characteristic syncytia formation and cell death due to fusion, as infected cells become fused with neighboring cells, which promotes intratumoral spread of the infection and releases additional immunogenic signals. In this review, we discuss the potential of fusogenic oncolytic viruses as optimal candidates to enhance immunotherapy and initiate broad antitumor responses. We provide an overview of the cytopathic mechanism of syncytia formation through viral-mediated expression of fusion proteins, either endogenous or engineered, and their benefits for cancer therapy. Growing evidence indicates that fusogenicity could be an important feature to consider in the design of optimal oncolytic virus platforms for combinatorial oncolytic immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.